82,651 Shares in InflaRx N.V. $IFRX Acquired by Concurrent Investment Advisors LLC

Concurrent Investment Advisors LLC bought a new stake in InflaRx N.V. (NASDAQ:IFRX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 82,651 shares of the company’s stock, valued at approximately $65,000. Concurrent Investment Advisors LLC owned about 0.12% of InflaRx as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in IFRX. Woodline Partners LP bought a new position in InflaRx during the first quarter valued at approximately $766,000. 683 Capital Management LLC raised its position in InflaRx by 26.8% in the 1st quarter. 683 Capital Management LLC now owns 2,625,000 shares of the company’s stock worth $2,678,000 after purchasing an additional 555,000 shares during the period. DAFNA Capital Management LLC bought a new stake in InflaRx in the first quarter worth $459,000. XTX Topco Ltd purchased a new stake in InflaRx during the first quarter valued at about $38,000. Finally, Cubist Systematic Strategies LLC grew its stake in shares of InflaRx by 33.9% during the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after buying an additional 7,616 shares during the last quarter. Institutional investors own 42.39% of the company’s stock.

InflaRx Stock Up 1.5%

Shares of InflaRx stock opened at $1.36 on Wednesday. InflaRx N.V. has a twelve month low of $0.71 and a twelve month high of $2.82. The company’s 50 day moving average is $1.29 and its 200 day moving average is $1.15. The company has a market cap of $91.30 million, a price-to-earnings ratio of -1.70 and a beta of 1.40.

InflaRx (NASDAQ:IFRX) last announced its earnings results on Thursday, August 7th. The company reported ($0.24) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.24). The company had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.02 million. Sell-side analysts expect that InflaRx N.V. will post -1.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

IFRX has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of InflaRx in a report on Tuesday, October 14th. HC Wainwright initiated coverage on InflaRx in a research report on Tuesday, September 2nd. They set a “buy” rating and a $6.00 price objective for the company. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $6.20.

InflaRx Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.